Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th
May 29, 2018
Stockholm – May 29, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies annual Healthcare Conference in New York on June 7th at 1.30PM EST, the presentation will be webcasted
Read more
Bulletin from the Annual General Meeting in Oncopeptides AB (Publ) Regulatory
May 17, 2018
Stockholm, Sweden – 17 May 2018 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2018 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolutions were passed
Read more
Oncopeptides AB Interim report January – March 2018 Regulatory
May 17, 2018
Stockholm — May 17, 2018 — Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2018 report
Read more
Oncopeptides has appointed a Clinical Advisory Board consisting of internationally recognized researchers within clinical development in hematology
April 23, 2018
Stockholm – April 23 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announced that the company has appointed a Clinical Advisory Board. The aim is to identify development opportunities both with Ygalo® within the planned first indication, new indications and for the further development of Oncopeptides' pipeline. Professor Paul G. Richardson, MD, will be chairman of this clinical advisory board. The other members are Dr. Lori A Kunkel, MD, Professor Axel Glasmacher, MD, and Dr. Christian Jacques, MD. Dr. Bengt Gustavsson, Head of Medical Relations for Oncopeptides will be the committee secretary
Read more
Oncopeptides Annual Report for 2017 Regulatory
April 18, 2018
Stockholm – April 18 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Annual Report for 2017 now is available at the company’s website: www.oncopeptides.com
Read more
Preparing for commercialisation of Ygalo®
April 18, 2018
Stockholm - 18 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) yesterday announced the notice for the AGM in which the Nomination Committee is proposing two new candidates for the Board of Directors. Per Wold-Olsen and Brian Stuglik will bring additional late-stage development and commercialisation experience to the company should the AGM vote in favour of the proposal. In conjunction with the AGM the proposal is furthermore that Alan Hulme will be stepping down as Chairman after eight successful years and handing over to Per Wold-Olsen as successor. Oncopeptides has over the last few years progressed from being a privatively held early-stage development company to a publicly listed biotechnology company engaged in pivotal trials and now preparing for stand-alone commercialisation in the field of haematology - oncology in the US and Europe. The Nomination Committee has therefore strived to further strengthen the profile of the Board of Directors with emphasis on commercial experience in the US pharmaceutical market
Read more
ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL) Regulatory
April 17, 2018
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, Thursday 17 May 2018 at 3.00 p.m. Coffee will be served starting at 2.00 p.m., at which time the registration for attendees will commence
Read more
First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo®
April 12, 2018
Stockholm - 12 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase I / II ANCHOR trial designed to study Ygalo® in multiple myeloma patients in combination with other drugs. This is an important study for creating understanding and knowledge among treating physicians for how Ygalo® can be used in Relapsed (RMM) and Relapsed Refractory Multiple Myeloma (RRMM) patients, and to open up for Ygalo® as a treatment option in earlier lines of treatment
Read more
Number of shares and votes in Oncopeptides Regulatory
March 29, 2018
Stockholm - March 29, 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 3,980,000 shares, which was carried out in March 2018
Read more
Oncopeptides strengthens its management team with Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer
March 26, 2018
Stockholm – March 26th, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President Clinical Strategy and Chief Scientific Officer (CSO). Dr Jacques has more than 25 years of experience in clinical development of new chemical entity’s within hematology-oncology leading to approval of several innovative pharmaceuticals in oncology and hematology, including pomalidomide
Read more